Evidence map›Paper›PMID 39967201›Full record

ArticleJACC. CardioOncology2025

Growth Differentiation Factor-15: A Promising Biomarker and Target in Cancer Patients.

Markus S Anker, Lars Bullinger, Ulrich Keller, Muhammad Shahzeb Khan

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. CardioOncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Markus S AnkerDeutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine CBF, Berlin, Germany; Charité - University Medicine Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany; Berlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin, Germany. Electronic address: markus.anker@charite.de.
Lars BullingerDepartment of Hematology, Oncology, and Cancer Immunology, Charité - University Medicine Berlin, corporate member of Free University Berlin and Humboldt University Berlin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Ulrich KellerDepartment of Hematology, Oncology, and Cancer Immunology, Charité - University Medicine Berlin, corporate member of Free University Berlin and Humboldt University Berlin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Muhammad Shahzeb KhanBaylor College of Medicine, Temple, Texas, USA; The Heart Hospital Plano, Plano, Texas, USA; Baylor Scott and White Research Institute, Dallas, Texas, USA. Electronic address: https://twitter.com/ShahzebKhanMD.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biomarkersbleedingcancerhemorrhagemajor bleedingrisk prediction

Identifiers

PMID39967201
PMCPMC11866430

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.